Glaukos iDose TR cuts eye pressure beyond cataract surgery alone, but will the advantage last?
Glaukos iDose TR shows an additional 3.6 mmHg pressure reduction with cataract surgery. Examine the Phase 4 data and adoption implications.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Glaukos has enrolled the PRESERFLO pivotal study, but the decisive U.S. evidence is still ahead
Glaukos completes PRESERFLO pivotal enrollment, shifting focus to 12-month data, FDA clearance and advanced glaucoma adoption.
Pharma & Biotech
Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows
Discover how Glaukos’ GLK-321 Phase 2 trial could reshape Demodex blepharitis care through a dropless eyelid-applied treatment.
Pharma & Biotech
What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
Glaukos secures a permanent J-code for Epioxa. Read why this reimbursement milestone could shape keratoconus treatment adoption and payer access.
Medical Devices & Diagnostics
Is Glaukos building a multi-franchise ophthalmology platform through Epioxa and glaucoma implants?
Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.